A significant federal policy change is now officially in effect that could improve access to medication for opioid use disorder (MOUD) across the United States. The U.S. Drug Enforcement Administration (DEA) has finalized regulations that permanently eliminate the former “X-waiver” requirement for clinicians prescribing buprenorphine for opioid use disorder, implementing changes first authorized by Congress in 2022.
For CASACs in New York State, this development has important clinical implications. Removing the additional registration requirement is intended to reduce administrative barriers and increase the number of healthcare providers able to offer evidence-based treatment for opioid use disorder. Expanded access to buprenorphine has the potential to improve treatment engagement, reduce overdose risk, and strengthen continuity of care, particularly in underserved and rural communities.
While easier access to medication is an important step, medication alone is not enough. Individuals receiving MOUD often benefit from comprehensive counseling, recovery support services, case management, and coordinated treatment planning. CASACs remain essential members of the interdisciplinary treatment team, providing assessment, motivational enhancement, relapse prevention, psychoeducation, and ongoing recovery support.
As New York continues to respond to the opioid crisis, expanding access to evidence-based medications while strengthening the behavioral health workforce offers an opportunity to improve outcomes for individuals, families, and communities. The NYS Association of CASAC Professionals will continue monitoring federal and state policy changes that affect substance use treatment and advocate for the critical role CASACs play in delivering comprehensive, person-centered care.
The rule also reinforces the importance of integrated, team-based care. While prescribing providers manage medication, CASACs provide the ongoing counseling, recovery planning, behavioral interventions, and therapeutic support that help individuals remain engaged in treatment. Medication for opioid use disorder is most effective when combined with person-centered counseling, recovery support services, and coordinated care that addresses housing, employment, mental health, family relationships, and other social determinants of health. Expanding access to buprenorphine should be viewed as strengthening the entire continuum of care, with CASACs continuing to play a central role in helping individuals achieve and sustain long-term recovery.
Final rule published by DEA and HHS: January 17, 2025.